CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Insurance coverage for weight-loss drugs has recently increased, but typically only covers branded versions, according to ...

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

Grey market grows for cheap weight-loss drugs imported from China Some users try small doses of substances not yet approved ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and ...

‘They hate it’: House Minority Whip describes Americans' rejection of Trump's tax bill Widow of officer who died by suicide ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.

Eli Lilly, the manufacturer of Zepbound, made Zepbound available on its online pharmacy, LillyDirect, in August 2024. The medication is available as a single-dose vial or an auto-injector pen.